[go: up one dir, main page]

WO2007052310A3 - Polymorphs of fexofenadine hydrochloride and process for their preparation - Google Patents

Polymorphs of fexofenadine hydrochloride and process for their preparation Download PDF

Info

Publication number
WO2007052310A3
WO2007052310A3 PCT/IN2006/000436 IN2006000436W WO2007052310A3 WO 2007052310 A3 WO2007052310 A3 WO 2007052310A3 IN 2006000436 W IN2006000436 W IN 2006000436W WO 2007052310 A3 WO2007052310 A3 WO 2007052310A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphs
preparation
fexofenadine hydrochloride
forms
fexofenadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000436
Other languages
French (fr)
Other versions
WO2007052310A2 (en
Inventor
Sanjay Suri
Tapan Kashyap
Jagat Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morepen Laboratories Ltd
Original Assignee
Morepen Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morepen Laboratories Ltd filed Critical Morepen Laboratories Ltd
Publication of WO2007052310A2 publication Critical patent/WO2007052310A2/en
Publication of WO2007052310A3 publication Critical patent/WO2007052310A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses two new polymorphs of Fexofenadine hydrochloride and a process preparing the same. The forms are designated by us as IXX and XX. The forms are prepared by contacting fexofenadine base with hydrogen chloride gas in presence of organic solvent followed by crystallization.
PCT/IN2006/000436 2005-11-03 2006-11-01 Polymorphs of fexofenadine hydrochloride and process for their preparation Ceased WO2007052310A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2942/DEL/2005 2005-11-03
IN2942DE2005 2005-11-03

Publications (2)

Publication Number Publication Date
WO2007052310A2 WO2007052310A2 (en) 2007-05-10
WO2007052310A3 true WO2007052310A3 (en) 2007-07-12

Family

ID=37948134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000436 Ceased WO2007052310A2 (en) 2005-11-03 2006-11-01 Polymorphs of fexofenadine hydrochloride and process for their preparation

Country Status (1)

Country Link
WO (1) WO2007052310A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104197A1 (en) 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
KR101513561B1 (en) * 2013-03-06 2015-04-21 주식회사 파마코스텍 A Novel Method for Preparing Fexofenadine HCl
CN104072402B (en) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 A kind of fexofenadine hydrochloride compound of new crystalline form and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738872A (en) * 1995-02-28 1998-04-14 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
WO2001094313A2 (en) * 2000-06-06 2001-12-13 Geneva Pharmaceuticals, Inc. Crystal modification of fexofenadine
WO2002066429A1 (en) * 2001-02-23 2002-08-29 Cilag Ag Method for producing non-hydrated fexofenadine hydrochloride and a novel crystalline form obtained thereby
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
WO2003011295A1 (en) * 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US20040077683A1 (en) * 2001-06-18 2004-04-22 Reddy M. Satyanarayana Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1- piperidinyl]-1-hydroxybutyl]-$g(a)-dimethylbenzene acetic acid and its hydrochloride
WO2005019175A1 (en) * 2003-08-26 2005-03-03 Cipla Limited Fexofenadine polymorphs and processes of preparing the same
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738872A (en) * 1995-02-28 1998-04-14 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
WO2001094313A2 (en) * 2000-06-06 2001-12-13 Geneva Pharmaceuticals, Inc. Crystal modification of fexofenadine
WO2002066429A1 (en) * 2001-02-23 2002-08-29 Cilag Ag Method for producing non-hydrated fexofenadine hydrochloride and a novel crystalline form obtained thereby
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20040077683A1 (en) * 2001-06-18 2004-04-22 Reddy M. Satyanarayana Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1- piperidinyl]-1-hydroxybutyl]-$g(a)-dimethylbenzene acetic acid and its hydrochloride
WO2003011295A1 (en) * 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
WO2005019175A1 (en) * 2003-08-26 2005-03-03 Cipla Limited Fexofenadine polymorphs and processes of preparing the same
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation

Also Published As

Publication number Publication date
WO2007052310A2 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
SG118370A1 (en) Improved process for the production of carbodiimide modified organic isocyanates
WO2009062044A3 (en) Processes for the preparation of prasugrel, and its salts and polymorphs
EP2145890A3 (en) Crystallization of hydrohalides of pharmaceutical compounds
WO2006127933A8 (en) Processes for preparing cinacalcet hydrochloride crystal form i
WO2006125026A3 (en) Process for preparing cinacalcet hydrochloride
IL183237A0 (en) Polymorphs of memantine hydrochloride
WO2007015017A3 (en) Novel polyquinoline derivatives and the therapeutic use thereof
SG118427A1 (en) Process for the preparation of polyamines of the diphenylmethane series at a low degree of protonation
EP1908749A4 (en) Process for production of isocyanate, isocyanate produced by the process, and use of the isocyanate
WO2006099468A3 (en) Process for the purification of duloxetine hydrochloride
WO2009025873A3 (en) Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl
IL176913A0 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
WO2010076810A3 (en) A process for the preparation of gefitinib
WO2009041473A1 (en) Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same
TW200720246A (en) Novel process for the preparation of acid chlorides
WO2009096668A3 (en) Improved process for preparing mycophenolate mofetil
HUP0501167A3 (en) Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2006071130A8 (en) A process for preparation of imatinib base
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
WO2006004976A3 (en) Process for the preparation of atomoxetine hydrochloride
WO2007052310A3 (en) Polymorphs of fexofenadine hydrochloride and process for their preparation
WO2005102999A3 (en) Crystalline forms of fexofenadine hydrochloride and processes for their preparation
EA200700766A1 (en) METHOD OF OBTAINING DERIVATIVES [1,4,5] -OXADIASEPINE
WO2009039241A3 (en) Improved process for preparing cinacalcet hydrochloride
WO2008004249A3 (en) An improved process for the preparation of clopidogrel and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06832294

Country of ref document: EP

Kind code of ref document: A2